Form 4: Korro Bio Director Boosts Stake with $4.9M Stock & Warrants

Korro Bio, Inc. Director and 10% owner Carmen Chang, through affiliated entities, acquired 207,100 shares of common stock and 242,945 pre-funded warrants for a total investment exceeding $4.9 million.

Summary

• Carmen Chang, a Director and 10% owner of Korro Bio, Inc., acquired additional securities through affiliated entities.
• On March 10, 2026, 207,100 shares of common stock were acquired at a price of $11.11 per share.
• Also on March 10, 2026, 242,945 pre-funded warrants were acquired at a price of $11.109 per warrant, with an exercise price of $0.001.
• These acquisitions were made from the Issuer pursuant to a Subscription Agreement dated March 9, 2026.
• The securities are indirectly beneficially owned through New Enterprise Associates 17, L.P. (NEA 17), where Carmen Chang is a manager of the general partner.
• Following these transactions, the indirect beneficial ownership includes 1,297,893 shares of common stock and 242,945 pre-funded warrants.
• The pre-funded warrants are immediately exercisable, subject to an ownership cap of 9.99% (or up to 19.99% with 61 days' prior notice).

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive signal, as a significant insider purchase by a director and 10% owner typically reflects high confidence in the company's prospects and valuation.

Positives

• A Director and 10% owner, Carmen Chang, increased her beneficial ownership in Korro Bio, Inc., signaling confidence in the company's future prospects.
• The acquisition of both common stock and pre-funded warrants represents a significant investment by an insider.
• The total investment for the reported transactions amounts to approximately $2,300,981 for common stock (207,100 shares * $11.11) and $2,698,990 for pre-funded warrants (242,945 warrants * $11.109), totaling over $4.9 million.

Risks

• The pre-funded warrants have an ownership limitation, preventing exercise if it would cause the holder to exceed 9.99% of common stock, which could limit immediate liquidity or control, though this can be increased to 19.99% with 61 days' notice.
• The value of the acquired securities is subject to market fluctuations and the overall performance of Korro Bio, Inc.

Future Outlook

This Form 4 filing does not contain explicit forward-looking statements or guidance from the company, as its purpose is solely to report insider transactions.

Industry Context

StockSavvy.ai notes that insider purchases, especially by a director and significant owner, can often be interpreted by the market as a positive signal, suggesting that those with intimate knowledge of the company believe its stock is undervalued or that significant positive developments are anticipated. In the biotechnology sector, such investments can be particularly impactful given the high-risk, high-reward nature of drug development and clinical trials.

Comparison to Industry Standards

• Insider buying activity, particularly by a director and 10% owner, is generally viewed favorably across all industries, including biotechnology.
• While specific comparable companies or projects are not mentioned in the filing, a significant investment of over $4.9 million by an insider suggests a strong belief in Korro Bio's future, which aligns with the behavior of confident insiders in successful growth-oriented companies.
• The acquisition of pre-funded warrants is a common strategy for large investors to gain exposure while managing immediate capital outlay and ownership thresholds, similar to practices seen in other high-growth sectors.

Related Party Transactions

• The acquisition of securities by Carmen Chang, a Director and 10% owner, from the Issuer (Korro Bio, Inc.) constitutes a related party transaction.
• The transaction was executed pursuant to a Subscription Agreement dated March 9, 2026.

Stakeholder Impact

• Shareholders: May view the insider purchase as a positive indicator of future stock performance and management confidence, potentially increasing investor sentiment.
• Company (Korro Bio, Inc.): Received capital from the sale of common stock and warrants, strengthening its financial position.

Key Dates

Recommendation

The substantial investment by a director and 10% owner, Carmen Chang, through affiliated entities, signals strong insider confidence in Korro Bio's future. Such significant insider buying, totaling over $4.9 million, often precedes positive developments or indicates a belief that the stock is undervalued, making it a compelling 'buy' signal for seasoned investors.

Keywords

Korro Bio, KRRO, Insider Trading, Form 4, Carmen Chang, Stock Purchase, Warrants, Beneficial Ownership, New Enterprise Associates, Biotechnology, Equity Investment